PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026

Contributed by: PR Newswire

Tags

HANSA-imlifidase-BLA

More Like This

Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA

Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation

Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients

Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting

Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results

Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results